BioSpace News Archive

The U.S. Food and Drug Administration (FDA) is wrapping up the month of September with a few PDUFA dates. Here’s a look.

The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look.

The company allegedly used a foundation as a conduit to pay the copays of Medicare patients who were taking Letairis, Gilead’s pulmonary arterial hypertension drug.

The move was announced due to the advisor’s role in overseeing a clinical study for Moderna’s mRNA vaccine candidate.

Notable, a functional precision medicine company, and myTomorrows, an integrated platform that links patients with an unmet medical need to treatments in development worldwide, are proud to announce their partnership.

KSQ Therapeutics to Present New Data from its USP1 Inhibitor Program at Upcoming EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics CAMBRIDGE, Mass.--( BUSINESS WIRE )-- KSQ® Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, announced it will present new data from its USP1 inhibitor pr

Hanger, Inc. (NYSE: HNGR) (the “Company”) today announced that Mark M. Jones, MD has been appointed to its Board of Directors, increasing the size of the Board to ten members, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200924005185/en/ Mark Jones, MD joins Hanger Board of Directors. (Photo: Business Wire) Dr. Jones curren

Radius Health, Inc., announced that Jose Carmona will be stepping down as Chief Financial Officer of Radius Health, Inc., with immediate effect.

CURE Pharmaceutical Holdings (OTC: CURR) today announced its definitive agreement to acquire Sera Labs, Inc. The closing is anticipated to occur in early October. As previously announced, the transaction consists of an up-front payment of $20 million, of which $1 million was paid in cash and $19 million has been allocated in CURE stock at a valuat

Fresenius Medical Care, the world’s leading provider of products and services for people with chronic kidney failure, today announced publication of its 2020 Global Annual Medical Report. Titled “The Power of Ideas: Ingenuity, Optimism, and the Future of Global Healthcare,” it advances the worldwide conversation about the contin